Adjuvant Therapy of Pemphigus

Archives of Dermatology

Volumn 120, Issue 7, 1984, Pages 941-951

  Bystryn, Jean Claude ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DAPSONE; GOLD; GOLD SALT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ADJUVANT THERAPY; ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; DRUG EFFICACY; DRUG THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTOXICATION; KIDNEY; NEPHROTOXICITY; PEMPHIGUS VULGARIS; PLASMAPHERESIS; REVIEW; SKIN TOXICITY; SURVEY; THERAPY;

ADRENAL CORTEX HORMONES; ANTIBODIES; AZATHIOPRINE; CELL COUNT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DAPSONE; DRUG EVALUATION; GOLD; HUMAN; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGUS; PLASMAPHERESIS; PLATELET COUNT; PROGNOSIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0021195709     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1984.01650430127024     Document Type: Article

References (69)

1. Thorn GW, Forsham PH, Frawley TF, et al: The clinical usefulness of ACTH and cortisone. N Engl J Med 1950;242:824-834, 865–872.
2. Costello MJ, Jaimovitch L, Dannenberg M: Treatment of pemphigus with corticosteroids. JAMA 1957;165:1249–1255.
3. Lever WF, White H: Treatment of pemphigus with corticosteroids: Results obtained in 46 patients over a period of 11 years. Arch Dermatol 1963;87:12–26.
4. Lever WF, Schaumburg-Lever G: Immunosuppressants and prednisone in pemphigus vulgaris. Arch Dermatol 1977;113:1236–1241.
5. Rosenberg FR, Sanders S, Nelson CT: Pemphigus: A 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976;112:962–970.
6. Ryan J-G: Pemphigus: 20-year survey of experience with 70 cases. Arch Dermatol 1971;104:14–20.
7. Sanders SL, Brodey M, Nelson CT: Corticosteroid treatment of pemphigus: Experience with 50 cases over a period of ten years. Arch Dermatol 1960;82:717–724.
8. Savin JA: Some factors affecting prognosis in pemphigus vulgaris and pemphigoid. Br J Dermatol 1981;104:415–520.
9. Krain LS: Pemphigus-epidemiologic and survival characteristics of 59 patients, 1959-1973. Arch Dermatol 1974;110:862–865.
10. Combes FC, Canizares O: Pemphigus vulgaris: A clinico- pathologic study. Arch Dermatol 1950;62:786–802.
11. Gellis S, Glass FA: Pemphigus: Survey of 170 patients admitted to Bellevue Hospital from 1911-1941. Arch Dermatol 1941;44:321–336.
12. Eller JJ, Kest LH: Pemphigus: Report of 77 cases. Arch Dermatol 1941;44:337–344.
13. Lever WF: Pemphigus. Medicine 1953;32:1–123.
14. Savin JA: International mortality from bullous diseases since 1950. Br J Dermatol 1976;94:179–189.
15. Hirone T: Pemphigus: A survey of 85 patients between 1970 and 1974. J Dermatol 1978;5:43–47.
16. Lever WF: Pemphigus and pemphigoid: A review of the advances made since 1964. Am Acad Dermatol 1979;1(1):2–31.
17. Penneys NS, Eaglstein WH, Frost P: Management of pemphigus with gold compounds: A long-term follow-up report. Arch Dermatol 1976;112:185–187.
18. O'Loughlin S, Goldman GC, Provost TT: Fate of pemphigus antibody following successful therapy: Preliminary evaluation of pemphigus antibody determinations to regulate therapy. Arch Dermatol 1978;114:1969–1972.
19. Lever WF, Talbott JH: Pemphigus. A clinical analysis and follow-up study of 62 patients. Arch Dermatol 1942;46:348–357.
20. Krain LS: Gold compounds versus corticosteroids in the treatment of pemphigus vulgaris. Arch Dermatol 1976;112:1466–1467.
21. Wittels W: Ergebnisse der Kortikosteroid-Therapie beim Pemphigus vulgaris. Derm Monatsschr 1960;141:401–410.
22. Ahmed AR, Graham J, Jordon RE, et al: Pemphigus: Current concepts. Ann Intern Med 1980;92:396–405.
23. Schiltz JR, Michel B, Papay R: Pemphigus antibody interaction with human epidermal cells in culture: A proposed mechanism for pemphigus acantholysis. J Clin Invest 1978;62:778–788.
24. Diaz LA, Marcelo CL: Pemphigoid and pemphigus antigens in cultured epidermal cells. Br J Dermatol 1978;98:631–637.
25. Farb RM, Dykes R, Lazarus GS: Anti-epithelial cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of protinase. Proc Natl Acad Sci USA 1978; 75:459–463.
26. Hashimoto K, Shatran KM, Weber PS, et al: Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. J Exp Med 1983;157:259–272.
27. Jablonska S, Chorzelski T, Blaszczyk M: Immunosuppressants in the treatment of pemphigus. Br J Dermatol 1970;83:315–323.
28. Van Dijk TJA, van Velde JL: Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica 1973;147:179–185.
29. Roenigk HH, Deodhor S: Pemphigus treatment with azathioprine: Clinical and immunological correlation. Arch Dermatol 1973;107:353–357.
30. Ebringer A, McKay IR: Pemphigus vulgaris successfully treated with cyclophosphamide. Ann Intern Med 1969;71:125–127.
31. McKelvey EM, Hasegawa J: Cyclophosphamide and pemphigus vulgaris. Arch Dermatol 1971;103:198–200.
32. Medved A, Maxwell I: Intermittent cyclophosphamide in pemphigus vulgaris and bullous pemphigoid. Can Med Assoc J 1974;111:245–250.
33. Parischa JS, Wood VD, Minocha Y: Treatment of pemphigus with cyclophosphamide. Br J Dermatol 1975;93:573–576.
34. Penn I: Tumor incidence in human allograft recipients. Transplant Proc 1979;11:1047–1051.
35. Notes and News: Anti-cancer drugs causing cancer. Lancet 1982;1:234.
36. Penneys NS: Gold therapy in pemphigus, in Briggaman RA, Goldsmith LA (eds): Progress in Dermatology, No. 6. Dermatology Foundation, 1978, vol 12, pp 31–34.
37. Rotstein H: Gold therapy for pemphigus vulgaris. Aust J Dermatol 1977;18:119–122.
38. Barrière H, Pasquiou C, Forest JL: Chrysotherapie du pemphigus. Ann Dermatol Venereol 1977;104:781–782.
39. Paltzile RL, Laude TA: Childhood pemphigus treated with gold. Arch Dermatol 1978;114:768–769.
40. Girdwood RH: Death after taking medicaments. Br Med J 1974;1:501–504.
41. Gumpel JM: Death associated with gold treatment: A reassessment. Br Med J 1978;1:215–216.
42. Freyberg RH, Ziff M, Baum J: Gold therapy for rheumatoid arthritis, in Hollander JL, McCarth DJ (eds): Arthritis and Allied Conditions, ed 8. Philadelphia, Lea & Febiger, 1972, pp 455–482.
43. Rothermich NO, Philips VK, Bergern W, et al: Chrysotherapy: A prospective study. Arthritis Rheum 1976;19:1321–1327.
44. Lockwood CM, Pearson TA, Rees AJ, et al: Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. Lancet 1976;1:711–715.
45. Dau PC, Lindstrom JM, Cassel CK, et al: Plasmaphersis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977;297:1134–1140.
46. Becker GJ, D'Apice AJ, Walker RG, et al: Plasmaphersis in the treatment of glomerulonephritis. Med J Aust 1977;2:693–696.
47. Bystryn J-C, Schenkein I, Uhr JW: A model for the regulation of antibody synthesis by serum antibody, in Amos B (ed): Progress in Immunology. New York, Academic Press Inc, 1977, vol 1, pp 627–636.
48. Auerbach R, Bystryn J-C: Plasmapheresis and immunosuppressive therapy. Arch Dermatol 1979;115:728–730.
49. Roujeau JC, Andre C, Fabre MJ, et al: Plasma exchange in pemphigus. Arch Dermatol 1983;119:215–221.
50. Bystryn J-C, Graf MW, Uhr JW: Regulation of antibody formation by serum antibody: II. Removal of specific antibody b means of exchange transfusion. J Exp Med 1970;132:1279–1287.
51. Cotterill JA, Barker DJ, Millard LG: Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978;98:231–232.
52. Ruocco V, Rossi A, Argenziano G, et al: Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol 1978; 98:237–241.
53. Meurer M, Braun Falco O: Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1979;100:231–232.
54. Swanson DL, Dahl MV: Pemphigus vulgaris and plasma exchange: Clinical and serologic studies. J Am Acad Dermatol 1981;4:325–328.
55. Jablonska S, Chorzelski T: When and how to use sulfones in bullous diseases. Int J Dermatol 1981;20:103–105.
56. Piamphongsant T: Pemphigus controlled by dapsone. Br J Dermatol 1976;94:681–686.
57. Seah PP, Fry L, Cairns RJ, et al: Pemphigus controlled by sulpha pyridine. Br J Dermatol 1973;89:77–81.
58. Knight AG, Black MM, Delaney TJ: Eosinophilic spongiosis: A clinical histological and immunofluorescence correlation. Clin Exp Dermatol 1976;1:141–153.
59. Haim S, Friedman-Birnbaum R: Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978;156:120–123.
60. Stevenson CJ: Treatment in bullous diseases with corticosteroid drugs and corticotrophin. Br J Dermatol 1960;72:11–21.
61. Linton WTR, Craig GE: Pemphigus: A comparison of the results of treatment at the Royal Victoria Hospital, Montreal, in the steroid and presteroid eras. Can Med Assoc J 1961;85:1192–1194.
62. Per MI, Mashkilleison AL: Remote results of continuous systemic corticosteroid treatment in pemphigus. Dermatologica 1962;124:99–109.
63. Wolff K: Immunosuppressive therapie bullöse. Dermatosen Hautart Suppl 1976;1:25–27.
64. O'Hara K: Treatment and prognosis of pemphigus. Rinsho Derma 1966;8:919–931.
65. Krain LS, Landau JW, Newcomer VD: Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972;106:657–661.
66. Block LJ, Caldarelli DD, Holinger PH, et al: Pemphigus of the air and food passages. Ann Otol Rhinol Laryngol 1977;86:584–587.
67. Fellner MJ, Katz JM, McCabe JB: Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris. Arch Dermatol 1978;114:889–894.
68. Piamphongsant T: Treatment of pemphigus with corticosteroids and cyclophosphamide. J Dermatol 1979;6:359–363.
69. Burton JH, Greaves MW: Azathioprine for pemphigus and pemphigoid: A four-year follow-up. Br J Dermatol 1974;91:103–109.